Fujiwara H, Tortolero-Luna G, Mitchell M F, Koulos J P, Wright T C
Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Cancer. 1997 Feb 1;79(3):505-12.
Although hormone receptor status is an important prognostic indicator in adenocarcinoma of the breast and the endometrium, few studies have investigated the expression and clinical significance of estrogen receptor (ER) and progesterone receptor (PgR) in adenocarcinoma of the cervix.
ER and PgR expression were determined using an immunohistochemical method in 84 cervical adenocarcinomas. Clinical features and outcome were determined by chart review.
ER was identified in 17 of the 84 cases (20%). ER positivity was most frequently detected in mucinous adenocarcinoma of the endocervical type (in 11 of 48 cases) and endometrioid adenocarcinoma (in 4 of 10 cases). PgR was identified in 23 of the 84 cases (27%). PgR positivity was also most frequently detected in mucinous adenocarcinoma of the endocervical type (in 15 of 48 cases) and endometrioid adenocarcinoma (in 6 of 10 cases). Mucinous adenocarcinoma of the intestinal type (five cases), glassy cell carcinoma (two cases), and clear cell adenocarcinoma (two cases) were uniformly negative for both ER and PgR. No association was detected between International Federation of Gynecology and Obstetrics stage and receptor status, but there was a somewhat lower frequency of ER positivity in poorly differentiated tumors (P = 0.07). No association was detected between PgR status and disease free survival. Similarly, no association between ER status and overall survival was observed. Although ER positive tumors may be associated with longer disease free survival than ER negative tumors, this difference did not reach statistical significance in this study (P = 0.06).
ER and PgR positivity were found in 20% and 27%, respectively, of primary cervical adenocarcinomas. However, receptor status was not significantly associated with either overall survival or disease free survival.
尽管激素受体状态是乳腺癌和子宫内膜癌重要的预后指标，但很少有研究探讨雌激素受体（ER）和孕激素受体（PgR）在宫颈腺癌中的表达及临床意义。
采用免疫组化方法检测84例宫颈腺癌中ER和PgR的表达。通过查阅病历确定临床特征和预后。
84例中有17例（20%）检测到ER。ER阳性最常见于宫颈内膜样黏液腺癌（48例中的11例）和子宫内膜样腺癌（10例中的4例）。84例中有23例（27%）检测到PgR。PgR阳性也最常见于宫颈内膜样黏液腺癌（48例中的15例）和子宫内膜样腺癌（10例中的6例）。肠型黏液腺癌（5例）、玻璃样细胞癌（2例）和透明细胞腺癌（2例）的ER和PgR均为阴性。国际妇产科联盟分期与受体状态之间未发现相关性，但低分化肿瘤中ER阳性的频率略低（P = 0.07）。未发现PgR状态与无病生存率之间存在相关性。同样，未观察到ER状态与总生存率之间存在相关性。尽管ER阳性肿瘤的无病生存期可能比ER阴性肿瘤长，但在本研究中这种差异未达到统计学意义（P = 0.06）。
原发性宫颈腺癌中ER和PgR阳性率分别为20%和27%。然而，受体状态与总生存率或无病生存率均无显著相关性。
